Xlife Sciences AG (SIX: XLS) announced that shareholders approved all proposals presented at the company's Annual General Meeting (AGM), where 3,134,367 voting shares, representing 54.3% of the total share capital, were represented. The approval underscores shareholder confidence in the company's strategic direction and recent achievements.
Chairman David L. Deck noted that the company strengthened its portfolio during the past year, highlighting two key milestones: the Nasdaq listing of portfolio company Veraxa Biotech (NASDAQ: VRXA) and the planned Landsteiner Scientific platform. These developments are expected to support the next phase of growth for Xlife Sciences.
The Landsteiner Scientific platform is strategically important as it aims to accelerate the identification and development of novel therapeutic approaches while improving global market access for Xlife Sciences' portfolio companies. Management explained that the platform will integrate academic research with commercial development, serving as a cornerstone of the company's future innovation pipeline. Additionally, the company outlined upcoming capital markets activities to further its objectives.
Xlife Sciences operates as an incubator and accelerator focused on value development and commercialization of promising research projects from universities and research institutions in the life sciences sector. The company targets high unmet medical needs and aims to bridge research and development to healthcare markets. It selects projects in four areas: technological platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health.
The shareholder approval and the company's strategic initiatives highlight its commitment to advancing life sciences innovations. For more information about Xlife Sciences, visit www.xlifesciences.ch.
